SCHEMBL4435670

SCHEMBL4435670

CN1C(=O)CC(=O)NC1=O.Cc1cc2cc(c1)C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.45
HSD17B10 Q99714 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MEN1 O00255 12/20 0.39
KMT2A Q03164 12/20 0.39
ALOX12 P18054 2/20 0.39
ALOX15 P16050 1/20 0.39
HBB P68871 1/20 0.39
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
PKM P14618 1/20 0.33
CYP2C19 P33261 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
POLB P06746 1/20 0.33
CRBN Q96SW2 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28255977 0.86 MAPT (0.45) MAPTHSD17B10L3MBTL1MEN1KMT2A
SCHEMBL1263340 0.82 CRBN (0.44) MAPTHSD17B10L3MBTL1MEN1KMT2A
SCHEMBL11049824 0.80 MAPT (0.42) MAPTHSD17B10L3MBTL1MEN1KMT2A
SCHEMBL9008187 0.75 MAPT (0.43) MAPTHSD17B10L3MBTL1MEN1KMT2A
SCHEMBL8428770 0.70 LMNA (0.36) MAPTHSD17B10L3MBTL1MEN1KMT2A
SCHEMBL6652471 0.68 YTHDF2 (0.40) MAPTHSD17B10L3MBTL1MEN1KMT2A
SCHEMBL29094161 0.67 MAPT (0.33) MAPTHSD17B10L3MBTL1MEN1KMT2A
SCHEMBL11741115 0.65 MEN1 (0.43) MAPTHSD17B10L3MBTL1MEN1KMT2A
Chloromethane SCHEMBL27796101 0.63 ALDH1A1 (0.35) ALDH1A1SMN1; SMN2POLB
SCHEMBL23602292 0.63 MAPT (0.39) MAPTHSD17B10L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108912057-A A method of barbituric acid derivatives are replaced by amine catalytic air oxidation green syt 5- hydroxyl -5- alkyl two 河南大学 2018-11-30 CN claimed
EP-2081576-A2 METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES Taro Pharmaceuticals North America, Inc. (KY) 2009-07-29 EP claimed
WO-2008066704-A2 METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) 2008-06-05 WO claimed
US-20080132529-A1 Method of improving bioavailability for non-sedating barbiturates TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-06-05 US claimed
CN-1291720-C Non-sedating barbituric acid derivatives TARO PHARMA IND (IL) 2006-12-27 CN claimed
EP-1485101-A4 NON-SEDATING BARBITURIC ACID DERIVATIVES TARO PHARMA IND (IL) 2006-04-12 EP claimed
US-6939873-B2 Non-sedating barbituric acid derivatives TARO PHARMACEUTICALS INDUSTRIES LIMITED (IL) 2005-09-06 US claimed
CN-1625401-A Non-sedating barbituric acid derivatives TARO PHARMA IND (IL) 2005-06-08 CN claimed
EP-1485101-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES Taro Pharmaceutical Industries Limited (IL) 2004-12-15 EP claimed
US-20030187005-A1 Non-sedating barbituric acid derivatives TARO PHARMACEUTICAL INDUSTRIES LTD. 2003-10-02 US claimed
WO-2003063872-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-08-07 WO claimed
CN-114144487-A Method and article for disposing adhesive onto a substrate 3M创新有限公司 2022-03-04 CN disclosed
CN-108912057-A A method of barbituric acid derivatives are replaced by amine catalytic air oxidation green syt 5- hydroxyl -5- alkyl two 河南大学 2018-11-30 CN disclosed
EP-2081576-A2 METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES Taro Pharmaceuticals North America, Inc. (KY) 2009-07-29 EP disclosed
US-20080132529-A1 Method of improving bioavailability for non-sedating barbiturates TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-06-05 US disclosed
US-6939873-B2 Non-sedating barbituric acid derivatives TARO PHARMACEUTICALS INDUSTRIES LIMITED (IL) 2005-09-06 US disclosed
CN-1625401-A Non-sedating barbituric acid derivatives TARO PHARMA IND (IL) 2005-06-08 CN disclosed
EP-1485101-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES Taro Pharmaceutical Industries Limited (IL) 2004-12-15 EP disclosed
US-20030187005-A1 Non-sedating barbituric acid derivatives TARO PHARMACEUTICAL INDUSTRIES LTD. 2003-10-02 US disclosed
WO-2003063872-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132529-A1 Method of improving bioavailability for non-sedating barbiturates MTNR1B, GABRB3, GABBR1 MAPT 1872/4885HSD17B10 914/4885L3MBTL1 1822/4885
US-20030187005-A1 Non-sedating barbituric acid derivatives GABRA5, GABRA1, GABRA3 MAPT 647/4885HSD17B10 1126/4885L3MBTL1 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.